Screening, diagnosis, and treatment of depression in patients with end-stage renal disease

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 6, 2007, Pages 1332-1342

  Cohen, Scott D ^a   Norris, Lorenzo ^b   Acquaviva, Kimberly ^c   Peterson, Rolf A ^c   Kimmel, Paul L ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

CHRONIC KIDNEY FAILURE; DEPRESSION; ELECTROCONVULSIVE THERAPY; GROUP THERAPY; HUMAN; KINESIOTHERAPY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; REVIEW;

DEPRESSION; ELECTROCONVULSIVE THERAPY; EXERCISE THERAPY; HUMANS; KIDNEY FAILURE, CHRONIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY, GROUP; SEROTONIN UPTAKE INHIBITORS;

EID: 36849077477     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03951106     Document Type: Article

References (100)

1. Hinrichsen GA, Lieberman JA, Pollack S, Steinberg H: Depression in hemodialysis patients. Psychosomatics 30: 284-289, 1989
2. Cukor D, Peterson RA, Cohen SD, Kimmel PL: Depression in end-stage renal disease hemodialysis patients. Nat Clin Pract Nephrol 2: 678-687, 2006
3. Craven JL, Rodin GM, Littlefield C: The Beck Depression Inventory as a screening device for major depression in renal dialysis patients. Int J Psychiatry Med 18: 365-374, 1988
4. Watnick S, Wang PL, Demadura T, Ganzini L: Validation of 2 depression screening tools in dialysis patients. Am J Kidney Dis 46: 919-924, 2005
5. Hedayati SS, Bosworth HB, Kuchibhatla M, Kimmel PL, Szczech LA: The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int 69: 1662-1668, 2006
6. Lowry MR, Atcherson E: A short-term follow-up of patients with depressive disorder on entry into home hemodialysis training. J Affect Disord 2: 219-227, 1980
7. Kimmel PL, Weihs KL, Peterson RA: Survival in hemodialysis patients: The role of depression. J Am Soc Nephrol 4: 12-27, 1993
8. Kimmel PL, Thamer M, Richard CM, Ray NF: Psychiatric illness in patients with end-stage renal disease. Am J Med 105: 214-221, 1998
9. Kimmel PL: Depression in patients with chronic renal disease: What we know and what we need to know. J Psychosom Res 53: 951-956, 2002
10. Kimmel PL: Psychosocial factors in dialysis patients. Kidney Int 59: 1599-1613, 2001
11. Smith MD, Hong BA, Robson AM: Diagnosis of depression in patients with end-stage renal disease: Comparative analysis. Am J Med 79: 160-166, 1985
12. Coyne JC, Fechner-Bates S, Schwenk TL: The prevalence, nature and co-morbidity of depressive disorders in primary care. Gen Hosp Psychiatry 16: 267-276, 1994
13. Snow V, Lascher S, Mottur-Pilson C: Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 132: 738-742, 2000
14. Blazer DG, Kessler RC, McGonagle KA, Swartz MS: The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am J Psychiatry 151: 979-986, 1994
15. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, Veis JH: Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis patients. Kidney Int 57: 2093-2098, 2000
16. Peterson RA, Kimmel PL, Sacks CR, Mesquita ML, Simmens SJ, Reiss D: Depression, perception of illness and mortality in patients with end-stage renal disease. Int J Psychiatry Med 21: 343-354, 1991
17. Boulware LE, Liu Y, Fink NE, Coresh J, Ford DE, Klag MJ, Powe NR: The temporal relation between depression symptoms, cardiovascular disease events and mortality in ESRD: Contribution of reverse causality. Clin J Am Soc Nephrol 1: 496-504, 2006
18. Kimmel PL, Peterson RA: Depression in patients with end-stage renal disease treated with dialysis: Has the time to treat arrived? Clin J Am Soc Nephrol 1: 349-352, 2006
19. Kaveh K, Kimmel PL: Compliance in hemodialysis patients: Multidimensional measures in search of a gold standard. Am J Kidney Dis 37: 244-266, 2001
20. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Boyle DH, Verme D, Umana WO, Veis JH, Alleyne S, Cruz I: Behavioral compliance with dialysis prescription in hemodialysis patients. J Am Soc Nephrol 5: 1826-1834, 1995
21. Miller GE, Cohen S, Herbert TB: Pathways linking major depression and immunity in ambulatory female patients. Psychosom Med 61: 850-860, 1999
22. Licinio J, Wong ML: The role of inflammatory markers in the biology of major depression. Mol Psychiatry 4: 317-327, 1999
23. Joyce P, Hawkes C, Mulder R: Elevated levels of acute phase plasma proteins in major depression. Biol Psychiatry 32: 1035-1041, 1992
24. Kimmel PL, Phillips TM, Simmeris SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236-244, 1998
25. Friend R, Hatchett L, Wadhwa NK, Suh H: Serum albumin and depression in end-stage renal disease. Adv Perit Dial 13: 155-157, 1997
26. Cohen SD, Kimmel PL: Nutritional status, psychosocial issues, and survival in hemodialysis patients. Contrib Nephrol 155: 1-17, 2007
27. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, Veis JH: Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int 54: 245-254, 1998
28. Christensen AJ, Wiebe JS, Smith TW, Turner CW: Predictors of survival among hemodialysis patients: Effect of perceived family support. Health Psychol 13: 521-525, 1994
29. Devins GM, Mann J, Mandin H, Paul LC, Hons RB, Burgess ED, Taub K, Schorr S, Letourneau PK, Buckle S: Psychosocial predictors of survival in ESRD. J Nerv Ment Dis 178: 127-133, 1990
30. Kimmel PL: Psychosocial factors in adult end-stage renal disease patients treated with hemodialysis: Correlates and outcomes. Am J Kidney Dis 35: S132-S140, 2000
31. Levenson JL, Glocheski S: Psychological factors affecting end-stage renal disease: A review. Psychosomatics 32: 382-389, 1991
32. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Boyle DH, Umana WO, Kovac JA, Alleyne S, Cruz I, Veis JH: Psychologic functioning, quality of life, and behavioral compliance in patients beginning hemodialysis. J Am Soc Nephrol 7: 2152-2159, 1996
33. Lopes AA, Albert JM, Young EW, Satayathum S, Pisoni RL, Andreucci VE, Mapes DL, Mason NA, Fukuhara S, Wikstrom B, Saito A, Port FK: Screening for depression in hemodialysis patients: Associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 66: 2047-2053, 2004
34. Kimmel PL, Peterson RA: Depression in end-stage renal disease patients treated with hemodialysis: Tools, correlates, outcomes, and needs. Semin Dial 18: 91-97, 2005
35. Akiskal MD: Dysthymia and cyclothymia in psychiatric practice a century after Kraepelin. J Affect Disord 62: 17-31, 2001
36. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Washington, DC, American Psychiatric Association, 1994
37. Keitner GI, Ryan CE, Miller IW, Kohn R, Epstein NB: 12-month outcome of patients with major depression and comorbid psychiatric or medical illness. Am J Psychiatry 148: 345-350, 1991
38. Klein ND, Taylor EB, Harding K, Dickstein S: Double depression and episodic major depression: Demographics, clinical characteristics and short-term outcome. Am J Psychiatry 145: 1226-1331, 1988
39. Black DW, Winokur G, Nasrallah A: Treatment and outcome in secondary depression: A naturalistic study of 1087 patients. J Clin Psychiatry 48: 438-441, 1987
40. Wuerth D, Finkelstein SH, Finkelstein FO: The identification and treatment of depression in patients maintained on dialysis. Semin Dial 18: 142-146, 2005
41. Wilson B, Spittal J, Heidenheim P, Herman M, Leonard M, Johnston A, Lindsay R, Moist L: Screening for depression in chronic hemodialysis patients: Comparison of the Beck Depression Inventory, primary nurse, and nephrology team. Hemodial Int 10: 35-41, 2006
42. O'Donell K, Chung J: The diagnosis of major depression in end stage renal disease. Psychosomatics 66: 38-43, 1997
43. Hegde A, Veis JH, Seidman A, Khan S, Moore J Jr: High prevalence of alcoholism in dialysis patients. Am J Kidney Dis 35: 1039-1043, 2000
44. Jaffe JA, Kimmel PL: Chronic nephropathies of cocaine and heroin abuse: A critical review. Clin J Am Soc Nephrol 1: 655-667, 2006
45. Abram HS, Moore GL, Westervelt FB Jr: Suicidal behavior in chronic dialysis patients. Am J Psychiatry 127: 1199-1204, 1971
46. McDade-Montez EA, Christensen AJ, Cvengros JA, Lawton WJ: The role of depression symptoms in dialysis withdrawal. Health Psychol 25: 198-204, 2006
47. Kurella M, Kimmel PL, Young BS, Chertow GM: Suicide in the United States end-stage renal disease program. J Am Soc Nephrol 16: 774-781, 2005
48. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 4: 561-571, 1961
49. Kroenke K, Spitzer R, Williams J: The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 16: 606-613, 2001
50. Radloff L: The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1: 385-401, 1977
51. Katon W: Will improving detection of depression in primary care lead to improved depressive outcomes? Gen Hosp Psychiatry 17: 1-2, 1995
52. Schade CP, Jones ER, Wittlin BJ: A ten-year review of the validity and clinical utility of depression screening. Psychiatr Serv 49: 55-61, 1998
53. Coyne JC, Thompson R, Palmer SC, et al: Should we screen for depression? Caveats and potential pitfalls. Appl Prev Psychol 9: 101-121, 2000
54. Palmer SC, Coyne JC: Screening for depression in medical care: Pitfalls, alternatives, and revised priorities. J Psychosom Res 54: 279-287, 2003
55. Whooley MA, Simon GE: Managing depression in medical outpatients. N Engl J Med 343: 1942-1950, 2000
56. Mann JJ: Drug therapy: The medical management of depression. N Engl J Med 353: 1819-1834, 2005
57. Watnick S, Kirwin P, Mahnensmith R, Concato J: The prevalence and treatment of depression among patients starting dialysis. Am J Kidney Dis 41: 105-110, 2003
58. Koo JA, Yoon JY, Joo MH, Lee HS, Oh JE, Kim SG, Seo JW, Lee YK, Kim HJ, Noh JW, Lee SK, Son BK: Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci 329: 1-5, 2005
59. Cohen LM, Tessier EG, Germain MJ, Levy NB: Update on psychotropic medication use in renal disease. Psychosomatics 45: 34-48, 2004
60. Finkelstein FO, Finkelstein SH: Depression in chronic dialysis patients: Assessment and treatment. Nephrol Dial Transplant 15: 1911-1913, 2000
61. Finkelstein FO, Watnick S, Finkelstein SH, Wuerth D: The treatment of depression in patients maintained on dialysis. J Psychosom Res 53: 957-960, 2002
62. Cohen SD, Perkins V, Kimmel PL: Psychosocial issues in ESRD patients. In: Handbook of Dialysis, 4th Ed., edited by Daugirdas J, Ing T, Boston, Little Brown, 2007, pp 455-461
63. Mai I, Stormer E, Bauer S, Krüger H, Budde K, Roots I: Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 18: 819-822, 2003
64. Breidenbach T, Hoffman MW, Becker T, Schlitt H, Klempnauer J: Drug interaction of St John's wort with cyclosporine. Lancet 355: 1912, 2000
65. Novotny T, Florianova A, Ceskova E, Weislamplova M, Palensky V, Tomanova J, Sisakova M, Toman O, Spinar J: Monitoring of QT interval in patients treated with psychotropic drugs. Int J Cardiol 117: 329-332, 2007
66. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH: QTc interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355: 1048-1052, 2000
67. Wyszynski A, Wyszynski B: Manual of Psychiatric Care for the Medically III, Washington, DC, American Psychiatric Press, 2005
68. Dheenan S, Venkatesan J, Grubb BP, Henrich WL: Effect of sertraline hydrochloride on dialysis hypotension. Am J Kidney Dis 31: 624-630, 1998
69. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK: Antidepressants in bipolar disorder: The case for caution. Bipolar Disord 5: 421-433, 2003
70. Goldberg JF, Truman CJ: Antidepressant-induced mania: An overview of current controversies. Bipolar Disord 5: 407-420, 2003
71. Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ: Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 161: 163-165, 2004
72. Ghaemi SN, Boiman EE, Goodwin FK: Diagnosing bipolar disorder and the effect of antidepressants: A naturalistic study. J Clin Psychiatry 61: 804-808, 2000
73. Healy D: Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72: 71-79, 2003
74. Isacsson G, Holmgren P, Ahlner J: Selective serotonin re-uptake inhibitor antidepressants and the risk of suicide: A controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 111: 286-290, 2005
75. Hall WD: How have the SSRI antidepressants affected suicide risk? Lancet 367: 1959-1962, 2006
76. Yuan Y, Tsoi K, Hunt RH: Selective serotonin reuptake inhibitors and the risk of upper gastrointestinal bleeding: Confusion or confounding? Am J Med 119: 719-727, 2006
77. Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L, Crowell MD, Keshavarzian A, Jones MP: Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal hemorrhage: A multicenter retrospective analysis. Aliment Pharmacol Ther 23: 937-944, 2006
78. Dalton SO, Johansen C, Mellemkjaer L: Use of selective serotonin reuptake inhibitors and risk of gastrointestinal bleeding: A population-based cohort study. Arch Intern Med 163: 59-64, 2003
79. Serebruarny VL: Selective serotonin reuptake inhibitors and increased bleeding risk: Are we missing something? Am J Med 119: 113-116, 2006
80. Spigset O: Adverse reactions of selective serotonin re-uptake inhibitors. Drug Saf 29: 277-287, 1999
81. Bailey JE, Potokar J, Coupland N, Nutt DJ: The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin reuptake inhibitor in man. J Psychopharmacol 9: 137-141, 1995
82. Ueda N, Yoshimura R, Shinkai K, Sakata Y, Nakamura J: Higher plasma 5-hydroxyindoleacetic acid levels are associated with SSRI-induced nausea. Neuropsychobiology 48: 31-34, 2003
83. Streltzer J: Diagnosis and treatment considerations in depressed dialysis patients. Clin Exp Dial Apheresis 7: 254-257, 1983
84. Kennedy SH, Craven JL, Roin GM: Major depression in renal dialysis patients: An open trial of antidepressant therapy. J Clin Psychiatry 50: 60-63, 1989
85. Blumenfield M, Levy NB, Spinowitz B, Charytan C, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, Goodman A, Bergstrom RF: Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med 27: 71-80, 1997
86. Levy NB, Blumenfield M, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, Goodman A, Bergstrom RR: Fluoxetine in depressed patients with renal failure and in depressed patients with normal renal function. Gen Hosp Psychiatry 18: 8-13, 1996
87. Wuerth D, Finkelstein SH, Kliger AS, Finkelstein FO: Chronic peritoneal dialysis patients diagnosed with clinical depression: Results of pharmacologic therapy. Semin Dial 16: 424-427, 2003
88. Wuerth D, Finkelstein SH, Ciarcia J, Peterson R, Kliger AS, Finkelstein FO: Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Am J Kidney Dis 37: 1011-1017, 2001
89. Weilburg JB: An overview of SSRI and SNRI therapies for depression. Managed Care 13: 25-33, 2004
90. Friend R, Singletary Y, Mendell NR, Nurse H: Group participation and survival among patients with end-stage renal disease. Am J Public Health 76: 670-672, 1986
91. Kouidi E, Iacovides A, Iordanidis P, Vassiliou S, Deligiannis A, Ierodiakonou C, Tourkantonis A: Exercise renal rehabilitation program: Psychosocial effects. Nephron 77: 152-158, 1997
92. van Vilsteren MC, Greef MH, Huisman RM: The effects of a low-to-moderate intensity pred-conditioning exercise programme linked with exercise counselling for sedentary hemodialysis patients in the Netherlands: Results of a randomized clinical trial. Nephrol Dial Transplant 20: 141-146, 2004
93. Williams S, Ostroff R: Chronic renal failure, hemodialysis, and electroconvulsive therapy: A case report. J ECT 21: 41-42, 2005
94. Cukor D, Friedman S: Towards the psychosocial treatment of depressed patients on dialysis. Internet J Nephrol 2(2), 2005, available from www.ispub.com, accessed October 1, 2006
95. Spigset O, Hagg S, Stegmayr B, Dahlqvist R: Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol 56: 699-703, 2000
96. Doyle GD, Lhaer M, Kelly JG, Byrne MM, Clarkson A, Zussman BD: The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand Suppl 350: 89-90, 1989
97. Seabolt JL, De Leon OA: Response to nefazodone in a depressed patient with end-stage renal disease. Gen Hosp Psychiatry 23: 45-46, 2001
98. Olyaei AJ, deMattos AM, Norman DJ, Bennett WM: Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy 18: 1356-1359, 1998
99. Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA: The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 56: 14-21, 1994
100. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan SK, Bennett WM: Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, 4th Ed., Versa Press, 1999